Navigation Links
Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference
Date:2/22/2011

PRINCETON, N.J., Feb. 22, 2011 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today announced that it will present at the 2nd Annual Morningstar/NYSSA Healthcare Conference on Thursday, February 24, 2011 at 10:00 a.m. ET.  Investors may access a live webcast of the presentation at www.covance.com.  In order to register and download any necessary software, please log on 10 minutes early.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.9 billion, global operations in more than 30 countries, and more than 10,000 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release (and in the webcast announced in this press release), which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue, earnings growth, and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories, fluctuations in currency exchange rates, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
2. Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56
3. Covance Reports Third Quarter Financial Results and Takes Actions to Strengthen Future Performance
4. Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R&D Alliance
5. Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
6. Covance Board Authorizes $250 Million Stock Buyback
7. Covance to Present at Morgan Stanley Global Healthcare Conference
8. Covance to Present at William Blair & Companys 30th Annual Growth Stock Conference
9. Covance to Present at Goldman Sachs 31st Annual Global Healthcare Conference
10. Covance To Present at the Deutsche Bank 35th Annual Health Care Conference
11. Covance To Present At The 20th Annual Global Healthcare Services Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... AVIV, Israel , March 27, 2017 ... on oncology and immunology, announced today that AGI-134, an immunotherapy ... announced acquisition of Agalimmune Ltd., will be featured at the ... in Washington, DC to be ... ...
(Date:3/27/2017)... March 27, 2017   Pulmatrix, Inc . (NASDAQ: PULM), ... address serious pulmonary diseases, today announced that it has added ... fibrosis and asthma to its Scientific Advisory Board . ... Richard B. Moss , MD, former chief of the ... Cystic Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... , March 27, 2017  BERG, a ... data-driven, biological research approach, today announced that ... the discovery of new data using a ... brown fat metabolism. Joslin Diabetes Center led ... Biology® platform for analysis of samples.  The ...
Breaking Medicine Technology:
(Date:3/28/2017)... ORANGE, Calif. (PRWEB) , ... March 28, 2017 ... ... of its leading physicians, Paul Yost, will begin serving as new board chair ... earlier this month. Yost will serve the remainder of soon-to-be former chair Mark ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ongoing effort ... has recently developed and published an informational resource that addresses frequently asked questions. ... common inquiries the site’s team of third party administrator (TPA) contributors regularly receives ...
(Date:3/28/2017)... Santa Monica, CA (PRWEB) , ... March 28, ... ... expert, Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer ... newest gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s ...
(Date:3/28/2017)... ... ... common and unwelcomed occurrence in people of all ages, genders and ethnicities. Dermatologist Dr. Sonoa ... dealing with excess skin oil. “Oily skin is a challenge to many of my patients. ... oily shine while keeping the skin fresh and clean,” says Dr. Au. , What causes ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have ... sleep apnea treatment, with or without a referral. Sleep apnea is often left untreated ... daytime sleepiness, morning headaches and chronic snoring. , Dr. Braasch seeks to raise ...
Breaking Medicine News(10 mins):